Growth Differentiation Factor-15: a New Biomarker in Cardiovascular Disease

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2009 Dec 22

PMID 20024638

Citations 19

Authors

Tibor Kempf

Kai C Wollert

Affiliations

Soon will be listed here.

Abstract

Growth differentiation factor-(GDF-)15 is a stress-responsive cytokine that is emerging as a biomarker of cardiac and vascular dysfunction and disease. Elevated circulating levels of GDF-15 identify high-risk individuals across the cardiovascular continuum, from stable coronary artery disease to acute coronary syndrome and heart failure. The association of GDF-15 with outcome in these conditions is independent of clinical risk factors and established biomarkers, including NT-proBNP (N-terminal pro-B-type natriuretic peptide) and troponin. The prognostic information provided by GDF-15 in cardiovascular disease may inform patient management, e.g., by identifying patients with non-ST segment elevation acute coronary syndrome who benefit from an invasive strategy, or by monitoring treatment response in heart failure. Future studies need to evaluate prospectively whether GDF-15, alone or as part of a multimarker strategy, can improve contemporary risk prediction algorithms and support therapeutic management of patients with cardiovascular disease.

Citing Articles

Modeling the Impact of Extracellular Vesicle Cargoes in the Diagnosis of Coronary Artery Disease.

McGranaghan P, Pallinger E, Fekete N, Maurovich-Horvat P, Drobni Z, Merkely B Biomedicines. 2025; 12(12.

PMID: 39767589 PMC: 11727391. DOI: 10.3390/biomedicines12122682.

Growth/differentiation factor 15 (GDF15) expression in the heart after myocardial infarction and cardioprotective effect of pre-ischemic rGDF15 administration.

Dogon G, Rigal E, Potel E, Josse M, Rochette L, Bejot Y Sci Rep. 2024; 14(1):12949.

PMID: 38839839 PMC: 11153639. DOI: 10.1038/s41598-024-63880-5.

Growth Differentiation Factor 15 (GDF-15), a New Biomarker in Heart Failure Management.

Sawalha K, Norgard N, Drees B, Lopez-Candales A Curr Heart Fail Rep. 2023; 20(4):287-299.

PMID: 37289373 DOI: 10.1007/s11897-023-00610-4.

GDF15 in Vascular and Liver Metabolic Disorders: A Novel Therapeutic Target.

Fiorucci S, Urbani G Recent Adv Inflamm Allergy Drug Discov. 2022; 16(2):55-59.

PMID: 36578252 DOI: 10.2174/277227081602221221113442.

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.

Toda Kato E, Morrow D, Guo J, Berg D, Blazing M, Bohula E Eur Heart J. 2022; 44(4):293-300.

PMID: 36303404 PMC: 10066747. DOI: 10.1093/eurheartj/ehac577.

References

Lainscak M, Anker S . Prognostic factors in chronic heart failure. A review of serum biomarkers, metabolic changes, symptoms, and scoring systems. Herz. 2009; 34(2):141-7. DOI: 10.1007/s00059-009-3211-z. View

Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B . Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J. 2009; 30(19):2346-53. DOI: 10.1093/eurheartj/ehp261. View

Morrow D, de Lemos J . Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007; 115(8):949-52. DOI: 10.1161/CIRCULATIONAHA.106.683110. View

Schlittenhardt D, Schober A, Strelau J, Bonaterra G, Schmiedt W, Unsicker K . Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004; 318(2):325-33. DOI: 10.1007/s00441-004-0986-3. View

Foley P, Stegemann B, Ng K, Ramachandran S, Proudler A, Frenneaux M . Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J. 2009; 30(22):2749-57. PMC: 2777028. DOI: 10.1093/eurheartj/ehp300. View

Brown D, Moore J, Johnen H, Smeets T, Bauskin A, Kuffner T . Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum. 2007; 56(3):753-64. DOI: 10.1002/art.22410. View

Thygesen K, Alpert J, White H, Jaffe A, Apple F, Galvani M . Universal definition of myocardial infarction. Circulation. 2007; 116(22):2634-53. DOI: 10.1161/CIRCULATIONAHA.107.187397. View

Braunwald E . Biomarkers in heart failure. N Engl J Med. 2008; 358(20):2148-59. DOI: 10.1056/NEJMra0800239. View

Wollert K, Kempf T, Peter T, Olofsson S, James S, Johnston N . Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007; 115(8):962-71. DOI: 10.1161/CIRCULATIONAHA.106.650846. View

10.

Bermudez B, Lopez S, Pacheco Y, Villar J, Muriana F, Hoheisel J . Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery. Cardiovasc Res. 2008; 79(2):294-303. DOI: 10.1093/cvr/cvn082. View

11.

Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T . Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007; 28(23):2858-65. DOI: 10.1093/eurheartj/ehm465. View

12.

Eggers K, Kempf T, Allhoff T, Lindahl B, Wallentin L, Wollert K . Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J. 2008; 29(19):2327-35. PMC: 2556729. DOI: 10.1093/eurheartj/ehn339. View

13.

Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P . Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology. 2008; 150(4):1688-96. DOI: 10.1210/en.2008-0952. View

14.

Maisel A, Mueller C, Adams Jr K, Anker S, Aspromonte N, Cleland J . State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10(9):824-39. DOI: 10.1016/j.ejheart.2008.07.014. View

15.

Ferrari N, Pfeffer U, Delleva R, Ambrosini C, Noonan D, Albini A . The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res. 2005; 11(12):4610-9. DOI: 10.1158/1078-0432.CCR-04-2210. View

16.

Secchiero P, Corallini F, Gonelli A, Delleva R, Vitale M, Capitani S . Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res. 2006; 100(1):61-9. DOI: 10.1161/01.RES.0000253975.76198.ff. View

17.

Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U . Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008; 178(5):534-41. DOI: 10.1164/rccm.200802-235OC. View

18.

Hochman J, Tamis J, Thompson T, Weaver W, White H, Van de Werf F . Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med. 1999; 341(4):226-32. DOI: 10.1056/NEJM199907223410402. View

19.

Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T . Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2008; 177(9):1018-25. DOI: 10.1164/rccm.200712-1786OC. View

20.

Xu J, Kimball T, Lorenz J, Brown D, Bauskin A, Klevitsky R . GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006; 98(3):342-50. DOI: 10.1161/01.RES.0000202804.84885.d0. View